Keywords
Psychiatry ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

703 Search results.

WHO-5 - WHO (Five) Well-Being Index

- 4/22/18 - 1 form, 1 itemgroup, 5 items, 30 languages
Itemgroup: Over the last two weeks
WHO (Five) Well-Being Index (1998 version) http://www.who-5.org Also called : WHO Five, WHO 5

Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia NCT01850953 - Eligibility

- 4/17/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
The objective of this study is to determine the mechanisms by which varenicline, an effective smoking cessation treatment, protects against relapse. Varenicline will be administered in smokers with schizophrenia and control smokers using a randomized, double-blind, cross-over design. Smokers will be asked to stop smoking overnight; the next day the ability to resist smoking will be assessed in a laboratory smoking lapse paradigm. Measures of tobacco craving, reinforcement and withdrawal-related cognitive dysfunction will be correlated with time to lapse. The results could have significant clinical implications by identifying mechanisms by which smokers with schizophrenia are at more risk for relapse than the general population, leading to the development of more effective smoking cessation therapies. ODM derived from: https://clinicaltrials.gov/show/NCT01850953

Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia NCT02011750 - Eligibility

- 4/4/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
This is an exploratory study in Egypt that will combine a treatment trial among early course schizophrenia (ECSZ) patients with key analyses suggested by rodent studies. Specifically, the study will test the provocative results from animal studies indicating an impact of Toxoplasma Gondii (TOX) exposure on novelty seeking. The study will also test whether exposure to TOX is associated with other cognitive and behavioral changes, as well as changes in overall social function. We will also explore the relative efficacy of Sodium Valproate (Depakote, DEP) in improving clinical and overall social function among TOX exposed and unexposed patients. ODM derived from: https://clinicaltrials.gov/show/NCT02011750

Eligibility Depressive Disorder, Major NCT02067299

- 3/17/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants; ODM derived from: https://clinicaltrials.gov/show/NCT02067299

Eligibility Depressive Disorder, Major NCT02473289

- 3/17/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder; ODM derived from: https://clinicaltrials.gov/show/NCT02473289

Eligibility Depressive Disorder NCT02498392

- 3/17/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress; ODM derived from: https://clinicaltrials.gov/show/NCT02498392

Eligibility Depressive Disorder NCT02405715

- 3/17/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Therapy With an Oxytocin Adjunct for Major Depression; ODM derived from: https://clinicaltrials.gov/show/NCT02405715

Eligibility Depressive Disorder NCT01916200

- 3/17/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01916200

Eligibility Depression NCT02505178

- 3/16/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Examining the Feasibility and Effectiveness of Case Manager Delivered Problem Solving Therapy on Late Life Depression; ODM derived from: https://clinicaltrials.gov/show/NCT02505178

Eligibility Depression NCT02501239

- 3/16/19 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Health At Every Size and Acceptance and Commitment Therapy vs. Behavioral Weight Loss for Obesity and Depression in Women; ODM derived from: https://clinicaltrials.gov/show/NCT02501239

Eligibility Depression NCT02475954

- 3/16/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Telehealth Cognitive Behavioral Therapy for Depression in Parkinson's Disease (PD); ODM derived from: https://clinicaltrials.gov/show/NCT02475954

Eligibility Depression NCT02458690

- 3/16/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02458690